Oppenheimer Maintains Outperform on Harmony Biosciences, Raises Price Target to $62
Oppenheimer analyst Francois Brisebois maintains Harmony Biosciences (NASDAQ:HRMY) with a Outperform and raises the price target from $55 to $62.
80 Biggest Movers From Yesterday
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume.
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Harmony Biosciences Announces Applications Open March 18 For 2022 Patients At The Heart Program
Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for people living with rare neurological diseases,
Looking Into Harmony Biosciences’s Return On Capital Employed
According to Benzinga Pro, during Q4, Harmony Biosciences (NASDAQ:HRMY) earned $22.71 million, a 336.11% increase from the preceding quarter. Harmony Biosciences also posted a total of $91.21 million in sales, a 12.98% increase since Q3.
Oppenheimer Initiates Coverage On Harmony Biosciences with Outperform Rating, Announces Price Target of $55
Oppenheimer analyst Francois Brisebois initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $55.
Harmony Biosciences Q3 Adj. EPS $0.51 Beats $0.28 Estimate, Sales $80.70M Beat $79.85M Estimate
Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.28 by 82.14 percent. This is a 464.29 percent increase over losses of $(0.14) per share